alpha-chymotrypsin and Vascular-Diseases

To evaluate changes on venous diameter and perimeter of lower limbs in chronic venous disorder (CVD) patients after different clinical treatments for four weeks.. Fifty-two female patients classified as C2,s or C2,3,s (CEAP classification) were allocated consecutively in three groups: Cirkan (40 mg of the root extract of Ruscus aculeatus + 100 mg of flavonoid hesperidine methylchalcone + 200 mg of vitamin C per pill); elastic compression stockings (ECS) and no treatment (NT). Diameters were determined by duplex ultrasound and perimeter with Leg-O-Meter.. After treatment, Cirkan significantly decreased popliteal vein and great saphenous vein (GSV) diameters bilaterally and ECS decreased popliteal vein diameter bilaterally and GSV and varices only on the left limb. Perimeters changed only with ECS. Clinical scores changed between Cirkan x NT and ECS x Cirkan. Disability score varied for ECS x NT and Cirkan x NT. chi2 test detected different distribution frequency for C3 and C2 classes according to treatment: ECS (both limbs) and Cirkan (only left limb). Varices and anatomical scores did not change.. ECS emerges as the most effective clinical treatment tested but improvements with Cirkan on vein diameter and CEAP class were also observed. Clinical scores improved due to pain relief and edema reduction (ECS). These findings point to a positive effect of Cirkan, suggesting that venotonic drugs should be taken into account in the treatment of CVD.

Topics: Adult; Anthropometry; Ascorbic Acid; Brazil; Cardiovascular Agents; Chi-Square Distribution; Chronic Disease; Chymotrypsin; Disability Evaluation; Drug Combinations; Female; Hesperidin; Humans; Lower Extremity; Middle Aged; Pain; Pain Measurement; Phytosterols; Popliteal Vein; Saphenous Vein; Stockings, Compression; Time Factors; Treatment Outcome; Trypsin; Ultrasonography, Doppler, Duplex; Vascular Diseases

Predictive power, for total and vascular mortality, of selected indices measured at baseline in the British National Diet and Nutrition Survey (community-living subset) of People Aged 65 Years and Over was tested. Mortality status and its primary and underlying causes were recorded for 1100 (mean age 76.7 (sd 7.5) years, 50.2% females) respondents from the baseline survey in 1994-5 until September 2008. Follow-up data analyses focussed especially on known predictors of vascular disease risk, together with intakes and status indices of selected nutrients known to affect, or to be affected by, these predictors. Total mortality was significantly predicted by hazard ratios of baseline plasma concentrations (per sd) of total homocysteine (tHcy) (95% CI) 1.19 (1.11, 1.27), pyridoxal phosphate 0.90 (0.81, 1.00), pyridoxic acid 1.10 (1.03, 1.19), alpha1-antichymotrypsin 1.21 (1.13, 1.29), fibrinogen 1.14 (1.05, 1.23), creatinine 1.20 (1.10, 1.31) and glycosylated Hb 1.23 (1.14, 1.32), and by dietary intakes of energy 0.87 (0.80, 0.96) and protein 0.86 (0.77, 0.97). Prediction patterns and significance were similar for primary-cause vascular mortality. The traditional risk predictors plasma total and HDL cholesterol were not significant mortality predictors in this age group, nor were the known tHcy-regulating nutrients, folate and vitamin B12 (intakes and status indices). Model adjustment for known risk predictors resulted in the loss of significance for some of the afore-mentioned indices; however, tHcy 1.34 (1.04, 1.73) remained a significant predictor for vascular mortality. Thus, total and primary vascular mortality is predicted by energy and protein intakes, and by biochemical indices including tHcy, independent of serum folate or vitamin B12.

Topics: Aged; Aged, 80 and over; Biomarkers; Cholesterol; Chymotrypsin; Creatinine; Diet Surveys; Dietary Proteins; Energy Intake; Female; Fibrinogen; Glycated Hemoglobin; Homocysteine; Humans; Male; Mortality; Nutritional Status; Prognosis; Proportional Hazards Models; Risk Factors; Survival Analysis; United Kingdom; Vascular Diseases; Vitamin B Complex

Topics: Adult; Ascorbic Acid; Chemical and Drug Induced Liver Injury; Chymotrypsin; Drug Combinations; Female; Flavonoids; Hesperidin; Humans; Leg; Peptide Hydrolases; Phytosterols; Trypsin; Vascular Diseases; Veins

Topics: Age Factors; Chronic Disease; Chymotrypsin; Ethanol; Feces; Humans; Microscopy, Electron; Pancreatitis; Recurrence; Regeneration; Time Factors; Vascular Diseases

Topics: Alveolar Process; Angiography; Anti-Inflammatory Agents; Arteriosclerosis; Arteriovenous Anastomosis; Capillary Permeability; Chymotrypsin; Endarteritis; Gingiva; Gingivitis; Humans; Maxillary Artery; Periodontal Diseases; Periodontium; Plethysmography; Protein Deficiency; Sodium Isotopes; Trypsin; Vascular Diseases

Topics: Chymotrypsin; Edema; Female; Humans; Male; Trypsin; Varicose Veins; Vascular Diseases

Topics: Administration, Cutaneous; Chymotrypsin; Female; Heparin; Humans; Ointments; Pregnancy; Thrombophlebitis; Varicose Veins; Vascular Diseases

Topics: Anticoagulants; Blood Circulation; Chymotrypsin; Humans; Phlebitis; Thrombophlebitis; Varicose Veins; Vascular Diseases; Vascular Surgical Procedures

Topics: Chymotrypsin; Deficiency Diseases; Hematologic Tests; Lymphedema; Peripheral Vascular Diseases; Vascular Diseases

Topics: Arteriosclerosis; Blood Vessels; Chymotrypsin; Disease; Hematologic Tests; Infusions, Intra-Arterial; Vascular Diseases

Topics: Acridines; Anti-Infective Agents, Local; Chymotrypsin; Debridement; Hematologic Tests; Peripheral Vascular Diseases; Trypsin; Vascular Diseases

Topics: Chymotrypsin; Humans; Peptide Hydrolases; Peripheral Vascular Diseases; Trypsin; Vascular Diseases